Three-dimensional texture analysis of contrast enhanced CT images for treatment response assessment in Hodgkin lymphoma: comparison with F-18-FDG PET.

PURPOSE To determine the diagnostic performance of three-dimensional (3D) texture analysis (TA) of contrast-enhanced computed tomography (CE-CT) images for treatment response assessment in patients with Hodgkin lymphoma (HL), compared with F-18-fludeoxyglucose (FDG) positron emission tomography/CT. METHODS 3D TA of 48 lymph nodes in 29 patients was performed on venous-phase CE-CT images before and after chemotherapy. All lymph nodes showed pathologically elevated FDG uptake at baseline. A stepwise logistic regression with forward selection was performed to identify classic CT parameters and texture features (TF) that enable the separation of complete response (CR) and persistent disease. RESULTS The TF fraction of image in runs, calculated for the 45° direction, was able to correctly identify CR with an accuracy of 75%, a sensitivity of 79.3%, and a specificity of 68.4%. Classical CT features achieved an accuracy of 75%, a sensitivity of 86.2%, and a specificity of 57.9%, whereas the combination of TF and CT imaging achieved an accuracy of 83.3%, a sensitivity of 86.2%, and a specificity of 78.9%. CONCLUSIONS 3D TA of CE-CT images is potentially useful to identify nodal residual disease in HL, with a performance comparable to that of classical CT parameters. Best results are achieved when TA and classical CT features are combined.

[1]  J. Rademaker Hodgkin's and non-Hodgkin's lymphomas. , 2007, Radiologic clinics of North America.

[2]  G. Salles,et al.  Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Sung Ho Hwang,et al.  Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy , 2013, European Radiology.

[5]  Andrzej Materka,et al.  Texture analysis for magnetic resonance imaging , 2006 .

[6]  Vicky Goh,et al.  Are Pretreatment 18F-FDG PET Tumor Textural Features in Non–Small Cell Lung Cancer Associated with Response and Survival After Chemoradiotherapy? , 2013, The Journal of Nuclear Medicine.

[7]  Ora Israel,et al.  18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients , 2010, Journal of Nuclear Medicine.

[8]  Andrzej Materka,et al.  Effects of MRI acquisition parameter variations and protocol heterogeneity on the results of texture analysis and pattern discrimination: an application-oriented study. , 2009, Medical physics.

[9]  V. Goh,et al.  Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. , 2011, Radiology.

[10]  Thomas C Kwee,et al.  Imaging in staging of malignant lymphoma: a systematic review. , 2008, Blood.

[11]  M. Kurrer,et al.  Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed? , 2007, Radiology.

[12]  E. Kerviler,et al.  From multislice CT to whole-body biomarker imaging in lymphoma patients , 2011, European Radiology.

[13]  Siegfried Trattnig,et al.  Texture‐based classification of focal liver lesions on MRI at 3.0 Tesla: A feasibility study in cysts and hemangiomas , 2010, Journal of magnetic resonance imaging : JMRI.

[14]  S. Mirzaei,et al.  Prognostic significance of the standardized uptake value of pre-therapeutic 18F-FDG PET in patients with malignant lymphoma , 2011, Medical oncology.

[15]  Jianhua Yao,et al.  CT grading of lung disease in lymphangioleiomyomatosis. , 2012, AJR. American journal of roentgenology.

[16]  C. Chatwin,et al.  Dynamic Contrast-Enhanced Texture Analysis of the Liver: Initial Assessment in Colorectal Cancer , 2011, Investigative radiology.

[17]  Mary M. Galloway,et al.  Texture analysis using gray level run lengths , 1974 .

[18]  J. Tian,et al.  Characterization of adrenal metastatic cancer using FDG PET/CT. , 2012, Neoplasma (Bratislava).

[19]  S. Hain,et al.  18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT , 2000, Leukemia & lymphoma.

[20]  L. Brepoels,et al.  PET and PET/CT for response evaluation in lymphoma: Current practice and developments , 2007, Leukemia & lymphoma.

[21]  Prasun Dastidar,et al.  Texture analysis on MRI images of non-Hodgkin lymphoma , 2008, Comput. Biol. Medicine.

[22]  P. Dupont,et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Higuchi,et al.  Prognostic impact of FDG-PET in surgically treated pathological stage I lung adenocarcinoma. , 2014, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[24]  Jeong Hyun Lee,et al.  Prognostic Value of Tumor 18F-FDG Uptake in Patients with Untreated Extranodal Natural Killer/T-Cell Lymphomas of the Head and Neck , 2008, Journal of Nuclear Medicine.

[25]  G. Jerusalem,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. , 1999, Blood.

[26]  J. Kuruvilla,et al.  Treatment of newly diagnosed advanced stage Hodgkin lymphoma. , 2012, Blood reviews.

[27]  G. Karanikas,et al.  Assessment of pulmonary melanoma metastases with 18F-FDG PET/CT: which PET-negative patients require additional tests for definitive staging? , 2012, European Radiology.

[28]  M K Markey,et al.  Application of the mutual information criterion for feature selection in computer-aided diagnosis. , 2001, Medical physics.

[29]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[30]  R. Hicks,et al.  Overview of early response assessment in lymphoma with FDG-PET , 2007, Cancer imaging : the official publication of the International Cancer Imaging Society.

[31]  R. Houot,et al.  Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  S. Iwano,et al.  What causes false-negative PET findings for solid-type lung cancer? , 2013, Lung cancer.

[33]  R.M. Haralick,et al.  Statistical and structural approaches to texture , 1979, Proceedings of the IEEE.

[34]  Peter Gibbs,et al.  Texture analysis in assessment and prediction of chemotherapy response in breast cancer , 2013, Journal of magnetic resonance imaging : JMRI.

[35]  K. Miles,et al.  Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival , 2012, European Radiology.